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ABSTRACT
The COVID-19 pandemic, characterised by a fast 
and global spread during the first months of 2020, 
has prompted the development of a structured set of 
recommendations for cancer care management, to 
maintain the highest possible standards. Within this 
framework, it is crucial to ensure no disruption to essential 
oncological services and guarantee the optimal care.
This is a structured proposal for the management of lung 
cancer, comprising three levels of priorities, namely: tier 
1 (high priority), tier 2 (medium priority) and tier 3 (low 
priority)—defined according to the criteria of the Cancer 
Care Ontario, Huntsman Cancer Institute and Magnitude of 
Clinical Benefit Scale.
The manuscript emphasises the impact of the COVID-19 
pandemic on lung cancer care and reconsiders all steps 
from diagnosis, staging and treatment.
These recommendations should, therefore, serve as 
guidance for prioritising the different aspects of cancer 
care to mitigate the possible negative impact of the 
COVID-19 pandemic on the management of our patients.
As the situation is rapidly evolving, practical actions are 
required to guarantee the best patients’ treatment while 
protecting and respecting their rights, safety and well- 
being. In this environment, cancer practitioners have great 
responsibilities: provide timely, appropriate, compassionate 
and justified cancer care, while protecting themselves 
and their patients from being infected with COVID-19. In 
case of shortages, resources must be distributed fairly. 
Consequently, the following recommendations can be 
applied with significant nuances, depending on the time 
and location for their use, considering variable constraints 
imposed to the health systems. An exceptional flexibility is 
required from cancer caregivers.
INTRODUCTION
The coronavirus disease 2019 (COVID-19), 
characterised by a respiratory tract infec-
tion caused by the severe acute respiratory 
syndrome coronavirus 2 (SARS- CoV-2) virus, 
to date has caused more than one million 
confirmed cases worldwide.1 This pandemic 
has forced all the healthcare stakeholders 
to urgently reorganise the management of 
patients with COVID-19, prioritising per 
value resources and therapeutic strategies.2 3
Since the beginning of the outbreak of 
COVID-19, the oncology community has been 
under pressure to protect cancer patients and 
ensure their treatment.4 5 This complex task 
required brings with it an emotional struggle 
as we balance the desire to cure or treat our 
patients, with the fear of losing them from 
infection.6
Several worldwide leading professional 
organisations, including the European Society 
of Medical Oncology (ESMO), have worked 
to implement and share knowledge about 
the importance of preventative/measures to 
maximise their support to our patients.4 7
Deciding whether to offer, postpone or 
even cancer or not treatments to patients, 
has become a crucial recurrent dilemma for 
lung cancer oncologists.4 8 Different cancer 
treatments require careful specific, individual 
assessment and consideration: for instance, 
chemotherapy may cause transient immune 
suppression, immunotherapy or tyrosine 
kinase inhibitors may trigger inflammatory 
lung changes, mimicking and worsening 
pulmonary symptoms.9 These inflammatory 
lung damage scenarios that are routinely 
faced in the contest of lung cancer care 
could potentially lead to a poorer outcome 
in case of concomitant COVID-19 disease. 
However, oncologists should weigh the risk 
of death for patients with lung cancer due to 
COVID-19, with the negative impact on their 
prognosis due to disruption of their cancer 
care.9 10 Oncologists should not ignore the 
risk of observing a bimodal peak of cancer 
patients dying: the imminent spike of those 
falling victim to COVID-19 and the latent toll 
on those experiencing an excess of cancer- 
related mortality, whose treatments were 
de- intensified, delayed or cancelled.
Considering that the duration of this 
pandemic is difficult to foresee, patient 
decisions have to be made by multidisci-
plinary teams. A multifactorial risk/benefit 
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evaluation, including the magnitude of the epidemic in 
the country, the local healthcare structure resources and 
the infection risk to the individual, must be carried out.11
In the present work, we report the ESMO recommenda-
tions for diagnosis, treatment and follow- up for patients 
affected by lung cancer during the COVID-19 pandemic. 
These recommendations should be used as guidance to 
prioritise the various aspects of cancer care and to miti-
gate the potential harm due to COVID-19 epidemic on 
patients with lung cancer.
METHODOLOGY FOR THE SELECTION OF PRIORITY 
INTERVENTIONS
The present manuscript reports the consensus of an 
international panel of thoracic malignancies experts in 
the management of lung cancer. It is proposed to guide 
healthcare professionals treating lung cancer patients 
during the COVID-19 pandemic. The expert consensus- 
based recommendations are not intended to replace the 
current guidelines but slightly adapt them to the evolving 
circumstances and constraints imposed by the COVID-19 
pandemic, using a value- based framework to set priori-
ties. The experts have formulated all the adaptations and 
prioritisations via teleconferences and email discussions.
With the aim to provide a framework for the response 
of the medical community to COVID-19, ESMO has estab-
lished guide for clinicians, defining three levels of prior-
ities regarding therapeutic interventions, namely: tier 1 
(high priority), tier 2 (intermediate priority) and tier 3 
(low priority)—informed by the Ontario Health Cancer 
Care Ontario framework of resource- prioritisation and by 
the ESMO Magnitude of Clinical Benefit Scale (MCBS), 
a public health tool intended to support the uptake of 
medical interventions in oncology.12 13
Overall, the prioritisation has been developed to incor-
porate both the information on the value- based prioritisa-
tion and clinical cogency of the responses.
 ► Tier 1 (high priority): patient’s condition is imme-
diately life- threatening, clinically unstable and/or 
the magnitude of benefit qualifies the intervention 
as high priority (eg, significant overall survival gain 
and/or substantial improvement of the quality of life 
(QoL));
 ► Tier 2 (medium priority): patient’s situation is non- 
critical but delay beyond 6 to 8 weeks could potentially 
impact the overall outcome and/or the magnitude of 
benefit qualifies for intermediate priority;
 ► Tier 3 (low priority): patient’s condition is stable 
enough allowing services to be delayed for the dura-
tion of the COVID-19 pandemic and/or the interven-
tion is non- priority based on the magnitude of benefit 
(eg, no survival gain with no change or reduced QoL).
The clinical guidance defined by ESMO must be inter-
preted and used in the broader context of local and 
international health system strategies and aligned to the 
Global Norms of WHO, the lead public health agencies 
and health technical governmental boards. Interventions 
to ensure the safest conditions for the health workforce, 
the proper provision of personal protective equipment, 
the testing strategy for healthcare personnel, patients 
and communities are essential and developed in parallel, 
conditioned by the local situation over time. Of note, 
population- based strategies and policies need to consider 
the most vulnerable communities explicitly for COVID-19 
infection and complications—cancer patients being first 
among them.13 14 Recently, the TERAVOLT registry 
revealed that patients with thoracic malignancies are less 
likely to be admitted to the intensive care unit and are at 
increased risk of prolonged hospitalisation and mortality, 
rising to 33% in this series, from COVID-19 infection. 
Univariate analyses revealed that the presence of chronic 
obstructive pulmonary disease was associated with a risk 
of hospitalisation and death. A multivariate analysis is that 
no patient treatments or cancer- related factors were asso-
ciated with a higher risk of death.15
PRIORITIES FOR LUNG CANCER PATIENTS
Outpatients visit priorities
The COVID-19 pandemic has been placing unprece-
dented pressure on health systems worldwide. To respect 
social distancing and to apply the overall public health 
measures for the mitigation of SARS- CoV-2 spread outpa-
tient cancer services should be reinforced and reorgan-
ised. This must occur balancing; first, the risks for cancer 
patient to contract COVID-19 during investigations and 
treatments and, second, the care providers’ capacity.
In the outpatient setting, prioritisation is guided by 
the magnitude of benefit. Clinical situation and quality 
of care should remain unchanged for the prioritised 
interventions.
For example, all treatment plans for patients with 
cancer must be discussed in a multidisciplinary setting as 
it has significant prognostic implications. Thus, while the 
format may change (eg, videoconferencing), the prin-
ciple of multidisciplinary shared care is non- negotiable.16
A quick triage for possible symptoms of COVID-19 
composed of a rapid questionnaire and temperature 
check should be put in place before entering any hospital 
premises.
To minimise the risk of exposure, outpatient visits 
should be reorganised: established patients with symp-
toms or patients with high suspicion of new lung cancer 
must be handled within standard pathways, ensuring 
protective measures are in place (eg, hand hygiene, phys-
ical distancing recommendations and use of personal 
protective equipment requested).17
Although hospital admission should be minimised, all 
the new cases with suspicion of clinical stage III or meta-
static, both for non- small cell lung cancer (NSCLC) or 
small cell lung cancer (SCLC), or the appearance of 
disease- related symptoms (eg, dyspnoea, cough, chest 
pain, haemoptysis and so on) should keep the standard 
work- up as per standard guidelines, without undue delay 
(high priority) (table 1).
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All non- priority outpatient appointments may be 
converted to the telemedicine platform, evaluating the 
priority on a clinical need basis. Telemedicine suits best 
the non- urgent situations for established patients without 
new complaints as well as patients on long- term follow- up 
with low/intermediate risk of relapse. In asymptomatic 
patients on follow- up, radiological investigation can be 
delayed unless new symptoms occur (medium priority).
For some of the patients on active treatment, whenever 
possible, the consultations should be shifted to telemed-
icine and blood tests performed at home. Overall, in the 
context of oncology care, telemedicine might represent 
a valuable tool to implement, but it should not entirely 
replace standard practice.
The patient- centred care model requires addressing 
of all patient’s needs and as such, psychosocial supports 
must be assured and converted to telemedicine or other 
web- based platforms if possible.
IMAGING
The role of imaging in lung cancer remains crucial for 
diagnosis and disease management. As recommended by 
the Centers for Disease Control and Prevention (CDC)17 
guidance and endorsed by the American College of Radi-
ologist (RCR),18 prioritising and safeguarding the health-
care resources is essential. Hence outpatient appoint-
ments and or imaging for non- critical patients, including 
a non- urgent diagnostic or image- guided procedure, 
should be postponed and rescheduled (low priority) 
(table 2).
Radiologists should closely work with their referring 
thoracic oncologists to review and reschedule such 
exams, based on patient’s priorities, prognosis and symp-
toms (low priority).
Similarly, considering the risk- benefit ratio lung cancer 
screening protocol with low- dose CT scan should be 
temporarily withheld during the pandemic peak or 
the appointments at least postponed by a few weeks or 
months depending on the local situation.
Furthermore, as reported by the National Health 
Service (NHS) of England guidelines for the manage-
ment of non- COVID-19 patients, alternative methods to 
monitor and review patients receiving systemic therapies 
should be explored. Nevertheless, slots for follow- up 
imaging within the first 6 months of lung cancer treat-
ment or in case of possible progression disease at any 
point in time should remain unchanged (high priority).
It is highly recommended that all patients suspicious for 
lung malignancy could have priority access to diagnostic 
imaging (eg, CT scan, positron emission tomography 
scan) (high priority). Whenever this was not feasible in 
a local hospital, a transfer to a cancer hub should be 
considered.
LUNG CANCER SURGERY
During the COVID-19 pandemic, the capacity of thoracic 
surgery has been significantly reduced and access to the 
intensive care unit after elective surgery might have been 
restricted. Due to these restrictions, setting up a priority- 
framework for lung cancer surgery is essential.
The multidisciplinary team plays an essential role to 
prioritise different lung cancer surgical procedures while 
preserving the highest possible standards. Once again, 
risk/benefit ratio, including not only patients and disease 
aspects19 but also alternative treatment modalities such 
as (chemo)radiation therapy for high volume disease 
or stereotactic ablative radiotherapy T1- T2N0 tumours, 
should be carefully explored (table 3).20 21
During the COVID-19 outbreak, keeping at bay the 
perioperative morbidity and mortality due to cancer or to 
SARS- CoV-2 infection should be a common goal. However, 
lung cancer is usually characterised by fast- growing 
behaviour; therefore, a rapid surgical assessment must be 
prioritised and carried out in particular if a delay could 
Table 1 Outpatient visit priorities
High priority Medium priority Low priority
New diagnosis or suspicion of invasive 
lung cancer with either:
 ► Disease- related symptoms 
(dyspnoea, pain, hemoptysis and so 
on)
 ► Suspicion of clinical stage III or 
metastatic NSCLC or SCLC
New diagnosis or suspicion of localised 
lung cancer of clinical stage I
Patients visits for psychological support 
(convert to telemedicine)
Survivorship visits
Follow- up for patients at high risk of 
relapse
Follow- up for patients at low/
intermediate risk of relapse
Visits for treatment administration Established patients with new problems 
or symptoms from treatment - convert as 
many visits as possible to telemedicine 
visits
Postoperative patients with no 
complications - convert as many visits as 
possible to telemedicine visits
NSCLC, non- small cell lung cancer; SCLC, small cell lung cancer.
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compromise the surgical outcome (high priority).22 High 
priority must also be given to specific palliative surgical 
approaches as thoracentesis or stent insertion, in case of 
significant symptoms and in order to improve QoL and 
patients’ prognosis.23–25
Surgical indications must be individualised, and all 
decisions should be shared with the patients and their 
caregivers: assessing preference and managing expecta-
tions while informing on the pros and cons of any plan 
in the context of the COVID-19 crisis remains crucial.26
EARLY STAGE NON-SMALL CELL LUNG CANCER
Improving outcomes in the curative setting of early stage 
remains a major therapeutic challenge in lung cancer 
management.
According to the ESMO- MCBS,13 pharmacological inter-
ventions in the curative setting are scored A, on a scale from 
A to C, from high to low priority, respectively. Therefore, 
the selection and prioritisation of the medical treatments 
at these stages require prudence and long- term vision as 
overall survival remains the most relevant endpoint.
Adjuvant platinum- based doublet chemotherapy, in 
resected stage I to III of NSCLC, showed an absolute 
benefit in survival at 5 years of about 5% to 6%.22 Since 
systemic treatments do not increase early mortality rates 
after surgery, tolerability and treatment adherence are 
critical factors for the optimum timing of chemotherapy 
in the COVID-19 era. Considering the risk of SARS- CoV-2 
infection related to peri- surgical and post- surgical time 
and different chemotherapy aspects (eg, immunosup-
pressive state), the role of adjuvant chemotherapy at the 
present time should be reconsidered, based on a priority 
scale that includes mainly the relative survival benefit and 
functional comorbidities (table 4).
Table 2 Imaging priorities for lung disease
High priority Medium priority Low priority
 ► Patients with significant respiratory 
symptoms and/or other clinically 
relevant chest, cancer- related 
or treatment- related symptoms. 
In patients with new respiratory 
symptoms such as dyspnoea, cough 
with or without fever, a CT scan is 
recommended
Follow- up imaging for high/intermediate 
risk of relapse in a year after completion 
of radical treatment
Follow- up imaging for high/intermediate 
risk of relapse more than one year after 
completion of radical treatment.
Standard staging work- up for suspected 
invasive cancer of unknown stage or 
stage II/III/IV
Standard staging work- up for early lung 
cancer (stage I)
Follow- up imaging after radical treatment 
in low- risk of relapse scenario.
Biopsies for suspicious nodules or mass 
for suspected invasive cancer of stage or 
stage III/IV
Biopsies for suspicious nodules or 
mass for suspected invasive cancer of 
unknown stage or stage I/II
Established patients with new problems 
or symptoms from treatment
Evaluation of active treatment response 
in the first 6 months of treatment or if 
suspicion of progression at any time 
point
Evaluation of active treatment response 
beyond 6 months of treatment if stable/
controlled situation
Follow- up of nodules of incidental finding 
with either:
 ► Solid nodule 50 to 500 mm3
 ► Pleural- based solid nodule
5 to 10 mm
 ► Partially solid nodule with a non- solid 
component of ≥8 mm
 ► Known VDT 400 to 600 days
Follow- up of nodules of incidental finding 
with either:
 ► Solid nodule <50 mm3
 ► Pleural- based solid nodule
<5 mm
 ► Partially solid nodule with a non- solid 
component of <8 mm
 ► Non- solid nodule <8 mm
 ► Benign morphology
 ► Known VDT>600 days
Pre- planned imaging evaluation per 
clinical trial protocol
Lung cancer screening can be deferred 
until the COVID-19 pandemic resolves - it 
is reasonable for patients in the general 
population to defer screening low- dose 
CT, a deferral that is not likely to have an 
impact on overall survival.
VDT, volume doubling time.
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The risk- benefit ratio of adjuvant chemotherapy should 
be thoroughly discussed with patients. The indication 
should be strongly considered in the presence of nega-
tive prognostic features (eg, lymphovascular infiltration, 
pathological lymph node invasion), while it should be 
withheld in frail, elderly patients with significant comor-
bidities. On the other hand, despite the risk of SARS- CoV-2 
infection related to chemotherapy- induced immunosup-
pression, adjuvant chemotherapy should be proposed in 
fit and young patients (≤65 years), with resected T3/T4 
or in case of pN2 disease.
Similarly, neoadjuvant chemotherapies should be given 
top priority, as reported by NHS clinical guide for the 
management non- coronavirus, in patients with cancer 
Table 3 Surgical oncology priorities for lung disease
High priority Medium priority Low priority
Drainage =/- pleurodesis of pleural effusion, 
pericardial effusion, tamponade risk
Evacuation of empyema- abscess
T2N0 tumours naïve from treatment or after 
induction chemotherapy
Discordant biopsies likely to be 
malignant
Discordant biopsies likely to be benign
Resectable T3/T4 tumours naïve from 
treatment or after induction chemotherapy
Resectable N1/N2 disease naïve from 
treatment or after induction chemotherapy
Operable pure GGO nodule (T1a)
Operable NSCLC with T1AN0 (alternative if 
no surgical capacity available is stereotactic 
radiotherapy; surgery is preferred)
Diagnostic procedure as mediastinoscopy / 
thoracoscopy / pleural biopsy / endoscopy 
/ transthoracic investigations for diagnostic/
staging workup
Diagnostic work- up and/or resection 
of nodules of incidental finding with 
either:
 ► Solid nodule >500 mm3
 ► Pleural- based solid nodule >10 
mm
 ► Solid component >500 mm3 in 
partially solid nodule
 ► Known VDT <400 days
 ► New solid component in pre- 
existing non- solid nodule
(alternative if no surgical capacity 
available is stereotactic radiotherapy)
Diagnostic work- up and/or resection of all other 
nodules of incidental finding including too:
 ► Solid nodule >500mm3 and known VDT >600 
days
(alternative if no surgical capacity available is 
stereotactic radiotherapy)
GGO, ground- glass opacity; NSCLC, non- small cell lung cancer; VDT, volume doubling time.
Table 4 Medical oncology priorities: early stage disease
High priority Medium priority Low priority
Concomitant chemo- radiotherapy for SCLC 
limited disease stage I/II
Neoadjuvant chemotherapy (enabling deferral 
of surgery by 3 months) in clinical stage II
Medical follow- up between two cycles should 
be performed only if necessary and by 
telephone
Adjuvant chemotherapy in T2B- T3N0 or 
pN1 disease should be discussed with 
patients considering clinical features and 
prognosis
Delivery of adjuvant chemotherapy 
in T3/4 or N2 disease for young (age 
≤65/70 years old)* and fit patients
Adjuvant chemotherapy in stage T1A- 
T2BN0 with negative prognostic features 
(lymphovascular infiltration, …)
Laboratory check between two cycles should 
be performed only if necessary and at home if 
possible
Adjuvant chemotherapy for elderly 
(older than 65 years old) and patients 
with important comorbidities should be 
discussed and possibility omitted
G- CSF use if febrile neutropenia risk evaluated 
more than 10% to 15%
*Defined elderly age according to local guidance.
G- CSF, granulocyte colony- stimulating factor; SCLC, small cell lung cancer.
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requiring acute treatment. This approach applies poten-
tially to all patients suitable for a surgical approach with 
curative intent, in particular, in young and fit patients 
without comorbidities. In adjuvant or neoadjuvant 
platinum- based chemotherapy, the use of granulocyte 
growth factors should be considered to avoid and mini-
mise neutropenia and its related risk of hospitalisation, 
possibly beyond the usual recommendations.27 28
LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER
The management of stage III of NSCLC is notably chal-
lenging during the COVID-19 pandemic, considering 
that the need to optimise and prioritise the appropriate 
combination, time and sequence of multiple treatment 
modalities, potentially lead to an increased risk of expo-
sure within hospitals to SARS- CoV-2.29
Given the significant curative potential, the treat-
ment for a patient with stage III NSCLC should receive 
high priority. These apply to neoadjuvant treatment in 
potentially resectable stage IIIA and to concomitant or 
sequential chemoradiation (CT/RT) in stage IIIA/IIIB/
IIIC, both supported by the use of granulocyte colony- 
stimulating factor (G- CSF) as previously proposed. Simi-
larly, as for patients with disease control after CT/RT 
treatment, the subsequent use of durvalumab as consoli-
dation therapy should be guaranteed within 42 days after 
CT/RT completion, without any planned delay (table 5).
A durvalumab infusion every 4 weeks instead of the 
standard every 2 weeks should be considered, where 
allowed from National Regulatory Agency (high priority).
METASTATIC NON-SMALL CELL LUNG CANCER
The definition of a homogeneous prioritisation algorithm 
in the metastatic setting is complex. In the clinical land-
scape of active treatments known to improve quality of 
life and survival in a very aggressive malignancy, evidence- 
based treatment approaches should retain priority 
even during the pandemic. Nowadays, the COVID-19 
outbreak represents an immediate threat to patients with 
NSCLC, but the possible disruption of cancer services 
might potentially outweigh the number of deaths from 
SARS- CoV-2 in the next years.11
According to the MCBS, the priority interventions in 
the advanced setting are scored 3, 4 or 5, in a descending 
scale for value, from 5 to 1.12 For such, the magnitude of 
benefit and the expected treatment benefits should guide 
the clinical indications and support treatment decisions.
In order to limit cancer- related mortality, in patients 
with a new diagnosis of metastatic NSCLC, all standard 
options for first- line systemic therapy should be envisaged 
unaltered, including chemotherapy, immunotherapy, 
tyrosine kinase inhibitors and different combinations. 
This approach aims to improve prognosis, cancer- related 
symptoms and QoL and should be prioritised whenever 
possible. The same holds true for second- line treatments 
in patients with symptomatic, progressive disease, whereas 
delaying the treatment could compromise patient's 
survival (high priority) (table 6).
In both settings, when the chosen treatment for clinical 
or biological criteria is chemotherapy, the use of G- CSF 
has to be considered if risk of febrile neutropenia is above 
>10% (high priority). This is not anticipated to impact on 
the specific COVID-19 risk but could reduce significantly 
risk of neutropenic sepsis hence number of hospital 
admissions for neutropenic sepsis.
Based on pharmacokinetic modelling and exposure- 
response analyses, immune checkpoint inhibitors (ICIs) 
schedule should be modified/delayed to reduce clinical 
visit, using 4- weekly nivolumab 480 mg30–34 or 6- weekly 
pembrolizumab 400 mg35–37, instead of the standard 
2- weekly or 3- weekly, when appropriate and where allowed 
from National Regulatory Agency (high priority).
For patients on ICI for more than 12/18 months, 
delaying the subsequent cycle, omitting some cycles or 
generally expanding intervals should be considered.37–40 
Discontinuation of ICIs after 2 years should be discussed, 
keeping in mind the lack of prospective evidence about 
optimal treatment duration in lung cancer.
The role of tyrosine kinase inhibitors (TKIs) in 
oncogene- driven NSCLC must continue unaltered, 
unless clinical situations require discontinuation (high 
Table 5 Medical oncology priorities: locally advanced disease
High priority Medium priority
Low 
priority
Concomitant chemo- radiotherapy for SCLC limited disease stage III
Concomitant or sequential chemo- radiotherapy for inoperable NSCLC 
Stage III
Starting consolidation durvalumab (within 42 days)
Neoadjuvant chemotherapy in clinical stage III Medical follow- up between two cycles 
should be performed only if necessary 
and by telephone
G- CSF use if febrile neutropenia risk evaluated more than 10% to 15% Laboratory check during treatment 
should be performed only if necessary 
and at home if possible
G- CSF, granulocyte colony- stimulating factor; NSCLC, non- small cell lung cancer; SCLC, small cell lung cancer.
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priority). A drug home delivery service should be insti-
tuted if possible for patients receiving oral TKIs to ensure 
similar drug access during the pandemic and unchanged 
care, while limiting access to hospital hence reducing the 
exposure to SARS- CoV-2
Home delivery service should be considered even in 
the case of oral chemotherapy treatments, which are 
preferred to the corresponding intravenous formula-
tions, when available, such as etoposide or vinorelbine, 
when clinically needed to reduce hospital admissions 
(medium priority).
Extra caution is required by systemic treatments that are 
less likely to impact overall survival or quality of life. A full 
explanation and assessment of risk/benefit ratio should 
be discussed with the patient on a case- by- case basis.
In this emergency scenario, a temporary withdrawal 
of some interventions could be contemplated. Antire-
sorptive bone- protective therapy (zoledronic acid, 
denosumab), not deemed urgent for malignant hyper-
calcaemia, should be withheld unless deliverable in the 
community or at the patient’s home (low priority).
SMALL CELL LUNG CANCER
SCLC treatment has always represented a challenge for 
the thoracic oncologist, considering the tumour aggres-
siveness, the rapid growth and early spread to distant 
metastases, sometimes associated with paraneoplastic 
syndromes.
As in the non- COVID-19 clinical setting, the treatment 
of SCLC should always be prioritised in patients suitable 
to receive first- line chemotherapy with or without ICIs 
for metastatic disease, or in patients with limited disease, 
treated concurrently with chest radiotherapy. G- CSF 
support is strongly indicated for patients who have a high 
or medium risk of febrile neutropenia (high priority) 
(tables 5 and 6).
Starting second- line therapy in a symptomatic and/
or platinum- refractory patient should be extensively 
discussed with the patient, weighing risk/benefit ratio.
The administration of prophylactic cranial irradia-
tion (PCI) should be potentially deferred in patients 
with limited stage, and replaced by MRI surveillance in 
patients with extensive disease SCLC.
RADIATION ONCOLOGY
The priority remains to guarantee that all curative 
treatments are unaffected by the COVID-19 pandemic. 
Recently the Royal College of Radiologist has issued 
guidelines on “Reduced fractionation in lung cancer 
patients treated with curative- intent radiotherapy during 
the COVID-19 pandemic”.41 They highlight the impor-
tance of discussing alternative dose- fractionation sched-
ules of radiotherapy techniques. Timing and ability to 
implement changes to dose/fractionation schedules 
will vary depending on resources and technology avail-
able and current capabilities. The objective is to identify 
reduced- fractionation and curative- intent radiotherapy 
regimes in lung cancer, assess their evidence base and 
provide organs- at- risk dose constraints. The aim is first to 
reduce hospital visits and exposure to SARS- CoV-2 and to 
increase radiotherapy unit capacity for operable patients 
Table 6 Medical oncology priorities: metastatic lung disease
High priority Medium priority Low priority
First- line treatment including, chemo, 
chemo plus IO, IO alone or TKIs to improve 
prognosis, cancer- related symptoms and QoL
Start second- line and beyond- line 
chemotherapy or IO in asymptomatic 
patients, in absence of threatening 
disease (volume/location).
Discontinuation of ICIs after 2 years of 
treatment should be suggested
Start second- line chemotherapy or IO in 
symptomatic and progressive disease 
patients.
Consider when feasible, oral 
chemotherapy treatment instead of 
intravenous (etoposide, vinorelbine) to 
reduce hospital visits
For patients ongoing with ICIs having 
stopped due to toxicity, resuming 
might be delayed in absence of 
disease progression
Start second- line TKI in progressive disease 
patients.
Medical follow- up between two cycles 
should be performed only if necessary 
and by telephone
Postpone antiresorptive therapy 
(zoledronic acid, denosumab) that is 
urgently for hypercalcaemia
G- CSF use has to be considered if despite 
optimal dose modification, a risk of febrile 
neutropenia is >10%
Blood check during treatment should 
be performed only if necessary and at 
home if possible
ICIs scheduled cycles may be modified/
delayed to reduce clinical visits (for instance, 
using 4 weekly or 6 weekly dosing instead 
of 2 weekly or 3 weekly for selected agents 
when appropriate (where allowed from 
National Regulatory Agency)
For patients ongoing with ICIs from 
more than 12/18 months, delaying 
the next cycle and omitting some 
scheduled cycles or generally enlarged 
intervals should be considered
G- CSF, granulocyte colony- stimulating factor; ICI, immune checkpoint inhibitors; IO, immune- oncology; QoL, quality of life; TKI, tyrosine 
kinase inhibitors.
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with lung cancer who may not be able to have surgery 
during this pandemic.
Furthermore, ESTRO- ASTRO has issued some recom-
mendations on how to adapt radiotherapy for lung 
cancer in the COVID-19 pandemic pointing out that all 
efforts should be made not to compromise the prognosis 
of lung cancer patients by departing from guideline- 
recommended radiotherapy practice.42
For instance, the adjuvant post- operative radiation 
therapy (PORT) for radically resected pN2 NSCLC 
should be discussed and eventually performed at the end 
of adjuvant chemotherapy or eventually delayed up to 3 
months from surgery (low priority) (table 7). The same 
therapeutic approach with PORT, in R1 resection, could 
be considered at the of adjuvant therapy or delayed up to 
3 months from surgery (medium priority).
For inoperable or locally advanced stage II to III lung 
cancers, the radiation, alone or with concurrent or 
sequential chemotherapy, should be delivered given the 
curative potential (high priority). At the same time, palli-
ative radiotherapy should not be denied or delayed in life- 
threatening or highly symptomatic clinical conditions, 
as superior vena cava obstruction, spinal cord compres-
sion, significant dyspnoea, bleeding or bone pain (high 
priority). Palliative RT with a single fraction or two frac-
tions could be considered as an alternative to longer frac-
tionation whenever possible.
The curative treatment for stage I lung cancer should 
be given with stereotactic body radiotherapy. In very early 
stage I patients, this treatment may be delayed in order to 
protect the patient by limiting hospital access during the 
pandemic peak (medium priority). A single fraction of 
30 to 34 Gy should be considered depending on tumour 
location.
As far as SCLC is concerned, MRI surveillance should 
be preferred to PCI for extensive- stage SCLC in order to 
reduce the number of visits (low priority); alternatively, 
PCI in limited- stage SCLC could be considered after 
chemotherapy (medium priority).
COVID-19 AND ITS IMPACT ON LUNG CANCER RESEARCH
Strict measures to limit the virus spread have affected clin-
ical cancer research centres that decreased their activity 
due to quarantine, working in shifts and lack of supplies. 
In some of these centres it was necessary to make deci-
sions of interrupting or even permanently stopping some 
trials in order to preserve the accuracy of endpoint eval-
uation and the protocol adherence. While clinical and 
translational research is crucial for providing the best 
care for cancer patients, many centres faced the need to 
modify programmes and adapt them to the new situation. 
Difficulties in trial conduction and monitoring may lead 
to specific and potentially critical protocol deviations. 
Despite this rapid evolution of the COVID-19, there is a 
strong need to respect several important aspects. First, all 
patients on trials should be ascertained a safe continu-
ation of protocol treatments. Second, all efforts should 
be made to protect patients by minimising unnecessary 
visits to cancer unit. Patients must consent to pursue their 
experimental trial care in the evolving COVID-19 situa-
tion after having been adequately informed about risk/
benefit ratios.
Nonetheless, the clinical trial investigating specific 
treatment for COVID-19 have been prioritised, following 
the absolute clinical need.43 44
In lung cancer research, enrolling or treating patients 
in trials with target therapy or ICIs should be prioritised, 
while reducing, if feasible, visits and planned hospital 
admission according to sponsors and clinical investigators.
To withdraw optional trial procedure and to allow flexi-
bility in visits, imaging assessments and laboratory checks 
should be considered via protocol amendments as neces-
sary. Trials with a placebo arm should be suspended until 
Table 7 Radiation oncology priorities for lung disease
High priority Medium priority Low priority
Radiotherapy for inoperable stage II to III cancers, with 
contraindications for chemotherapy.
SABR - SBRT for stage I cancers
Concomitant (preferred) chemo- radiotherapy for 
inoperable NSCLC Stage II/III. -
Adjuvant PORT for R1 resection, 
if indicated in NSCLC could be 
considered at the end of adjuvant 
chemotherapy or delayed up to 3 
months from surgery
Adjuvant PORT N2 R0, if indicated 
in NSCLC should be discussed 
and if retained considered at the 
end of adjuvant chemotherapy 
or delayed up to 3 months from 
surgery
Concomitant (preferred) chemo- radiotherapy for SCLC 
limited disease
PCI in limited SCLC after 
chemotherapy
PCI in extensive stage SCLC after 
chemotherapy should be replaced 
by MRI active surveillance
Superior vein cave obstruction or significant 
haemoptysis, spinal cord compression or any 
threatening lesion amenable to radiation therapy
NSCLC, non- small cell lung cancer; PCI, prophylactic cranial irradiation; PORT, post- operative radiation therapy; SABR, stereotactic ablative 
radiotherapy; SBRT, stereotactic body radiotherapy; SCLC, small cell lung cancer.
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the pandemic resolves, as exposing patients to the risk of 
SARS- CoV-2 in this context would be difficult to justify
To properly manage clinical trials during the COVID-19 
pandemic, the leading regulatory agencies such as the US 
Food and Drug Administration (FDA) and the European 
Medicines Agency (EMA) have issued guidelines and 
recommendations for a safe delivery of the study medi-
cations and a structural information on changes and 
protocol deviations.45 46
CONCLUSION
The COVID-19 has put a strain on the global health-
care system leading to an unprecedented modification 
of patient care and access to health services. During this 
pandemic, maintaining cancer care has represented 
a challenge that has required careful weighing of the 
COVID-19 risk and the optimal oncological standards.47
The oncology community has been forced to adapt 
cancer care and identify new strategies and priorities to 
ensure the highest possible therapeutic standards for our 
patients. Following the WHO indications, the develop-
ment of a framework to provide clear guidance on health-
care priorities, to support and enable decision- making 
when resources need to be rationed and cautiously allo-
cated. Any possible modification of a treatment schedule 
should entail a multidimensional assessment adapted to 
local resources, comprising clinical and tumour char-
acteristics, therapeutic objective and the potential risks 
associated with COVID-19 infection.
The ESMO clinical recommendations for lung cancer 
management are, in this context, a guide to ensure and 
maintain high- quality standards for our patients.
Unfortunately, to date, robust data are lacking to guide 
adjustments to standard- of- care in patients with lung 
cancer. Individualised treatment strategies and close 
follow- up are needed to reduce the gaps of COVID-19 
in our patients and to improve evidence- based approach 
and policies during this pandemic.
Useful and updated information can be found at 
https://www. esmo. org/ guidelines/ cancer- patient- 
management -  dur ing -  the -  cov id -  19 -  pandemic/ 
lung- cancer- in- the- covid- 19- era
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